Continued Ventilation During Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) is well known to induce a strong anti-inflammatory response. The investigators examined whether continued mechanical ventilation during CPB alters systemic immune activation.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
|Official Title:||Continued Mechanical Ventilation During CABG Operation Attenuates Systemic Immune Modulation|
- Alteration of soluble ST2 concentration in serum [ Time Frame: Preoperative, postoperative, day 1, day 2, day 3, day 4, day 5 after surgery ] [ Designated as safety issue: No ]Concentration of soluble ST2 will be assessed in the serum of patient´s preoperativem, postoperative and the following five consecutive days after surgery.
|Study Start Date:||April 2009|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Experimental: Ventilation Group
Volume controlled ventilation was done during the whole surgery.
Other: Lung Ventilation
In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
No Intervention: Non-ventilation Group
In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Other: Non-ventilated Group
. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Cardiopulmonary bypass is well known to induce a strong anti-inflammatory response. Studies had been shown that the contact of blood components with artificial surfaces, the surgical trauma, endotoxemia and a reperfusion injury are in part responsible for the seen immunological affect after surgery. The purpose of this study is to test the effect of continued mechanical ventilation during surgery on a blood marker called soluble ST2 in patients sera. Soluble ST2 acts as a decoy receptor of IL-33 and has anti-inflammatory effects. Elevated soluble ST2 concentrations are reported in patients with acute myocardial infarction, sepsis, congestive heart failure and elevates soluble ST2 levels are associated with adverse outcome.
|Medical University of Debrecen|
|Debrecen, Hungary, Nagyerdei krt. 98|
|Principal Investigator:||Hendrik Jan Ankersmit, MD||Medical University of Vienna|